<DOC>
	<DOCNO>NCT00640094</DOCNO>
	<brief_summary>Background : Experimental study document beneficial effect endogenously produce antioxidant , melatonin , reduce tissue damage limit cardiac pathophysiology model experimental ischemia-reperfusion . Melatonin confers cardioprotection ischemia-reperfusion injury likely direct free radical scavenging activity indirect action stimulate antioxidant enzyme . These action melatonin permit reduce molecular damage limit infarct size experimental model transient ischemia subsequent reperfusion . Study design : The Melatonin Adjunct acute myocaRdial Infarction treat Angioplasty ( MARIA ) trial prospective , randomize , double-blind , placebo-controlled , phase 2 study intravenous administration melatonin . The primary efficacy end point study determine whether melatonin treatment reduces infarct size determined cardiac magnetic resonance 5-7 day post-reperfusion . Other secondary end point clinical event occur within first year : death , sustain ventricular arrhythmia , resuscitation cardiac arrest , cardiogenic shock , heart failure , major bleeding , stroke , need revascularization , recurrent ischemia , re-infarctions rehospitalization ; change leave ventricular ejection fraction baseline 4 month follow-up . Implications : The MARIA trial test novel pharmacologic agent , melatonin , patient acute myocardial infarction hypothesis confer cardioprotection ischemia-reperfusion injury . If successful , find would support use melatonin therapy ischemic-reperfusion injury heart .</brief_summary>
	<brief_title>The Melatonin Adjunct Acute myocaRdial Infarction Treated With Angioplasty</brief_title>
	<detailed_description>See article detailed description : Contemporary Clinical Trials 28 ( 2007 ) 532-539</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>1 . Aged 18 75 year . 2 . Having experience continuous ischemic ( cardiac ) symptom least 20 minute . 3 . Having onset symptom qualify acute myocardial infarction within past 6 hour expect undergo primary angioplasty . 4 . Having electrocardiogram indicative acute ST segment elevation myocardial infarction showing : &gt; 2 mm ST segment elevation 2 anterior lateral lead ; &gt; 2 mm ST segment elevation 2 inferior lead couple ST depression 2 contiguous anterior lead total ST deviation &gt; 8 mm ; new leave bundle branch block least 1 mm concordant ST elevation . 5 . Being willing provide inform consent ( informed consent may provide legally authorize representative patient able provide accord local ethical standard ) . 6 . Being willing able follow least 3 month evaluation . A patient ineligible study entry he/she meet follow criterion : 1. prehospital thrombolysis , 2 . Killip class IV admission , 3. know history prior myocardial infarction , 4. know history renal failure , 5. history severe allergic reaction , 6. history autoimmune disease , 7. pregnancy , 8. severe concurrent illness reduce shortterm prognosis , 9. inability give inform consent 10. participation another study within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Melatonin</keyword>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Primary angioplasty</keyword>
</DOC>